Molecular Targets of Naturopathy in Cancer Research: Bridge to Modern Medicine

Nutrients

Volumn 7, Issue 1, 2015, Pages 321-334

  Ahmad, Aamir ^a   Ginnebaugh, Kevin R ^a   Li, Yiwei ^a   Padhye, Subhash B ^b   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MCE Society's Abeda Inamdar Senior   (India)

Author keywords

Cancer; Naturopathy; Nutraceuticals

Indexed keywords

BETA CATENIN; CURCUMIN; CYCLIC AMP; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX METALLOPROTEINASE; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; NUTRACEUTICAL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; RESVERATROL; SOMATOMEDIN; SONIC HEDGEHOG PROTEIN; STAT3 PROTEIN; SURVIVIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; WNT PROTEIN; ANTINEOPLASTIC AGENT;

ALTERNATIVE MEDICINE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOAVAILABILITY; CANCER RESEARCH; CLINICAL EFFECTIVENESS; CYTOTOXICITY; DRUG DESIGN; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; EVIDENCE BASED PRACTICE; HUMAN; PLEIOTROPY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; DIET SUPPLEMENTATION; DRUG RESISTANCE; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROCEDURES;

ANTINEOPLASTIC AGENTS; DIETARY SUPPLEMENTS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NATUROPATHY; NEOPLASMS; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84920511889     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu7010321     Document Type: Article

References (95)

1. Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64, 9–29.
2. Melisi, D.; Piro, G.; Tamburrino, A.; Carbone, C.; Tortora, G. Rationale and clinical use of multitargeting anticancer agents. Curr. Opin. Pharmacol. 2013, 13, 536–542.
3. Ahmad, A.; Sakr, W.A.; Rahman, K.M.W. Mechanisms and therapeutic implications of cell death induction by indole compounds. Cancers 2011, 3, 2955–2974.
4. Sarkar, F.H. Nutraceuticals and Cancer; Springer: New York, NY, USA, 2012; Volume 1
5. Shukla, Y.; George, J. Combinatorial strategies employing nutraceuticals for cancer development. Ann. N. Y. Acad. Sci. 2011, 1229, 162–175.
6. Russo, G.L. Ins and outs of dietary phytochemicals in cancer chemoprevention. Biochem. Pharmacol. 2007, 74, 533–544.
7. Brisdelli, F.; D’Andrea, G.; Bozzi, A. Resveratrol: A natural polyphenol with multiple chemopreventive properties. Curr. Drug Metab. 2009, 10, 530–546.
8. Deep, G.; Agarwal, R. Antimetastatic efficacy of silibinin: Molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev. 2010, 29, 447–463.
9. Ahmad, A.; Sakr, W.A.; Rahman, K.M. Novel targets for detection of cancer and their modulation by chemopreventive natural compounds. Front. Biosci. (Elite Ed.) 2012, 4, 410–425.
10. Soni, D.; Salh, B. A neutraceutical by design: The clinical application of curcumin in colonic inflammation and cancer. Scientifica (Cairo) 2012, 2012, doi:10.6064/2012/757890.
11. Shehzad, A.; Lee, Y.S. Molecular mechanisms of curcumin action: Signal transduction. Biofactors 2013, 39, 27–36.
12. Gupta, S.C.; Patchva, S.; Aggarwal, B.B. Therapeutic roles of curcumin: Lessons learned from clinical trials. AAPS J. 2013, 15, 195–218.
13. Borriello, A.; Bencivenga, D.; Caldarelli, I.; Tramontano, A.; Borgia, A.; Zappia, V.; Della Ragione, F. Resveratrol: From basic studies to bedside. Cancer Treat. Res. 2014, 159, 167–184.
14. Russo, G.L.; Russo, M.; Spagnuolo, C.; Tedesco, I.; Bilotto, S.; Iannitti, R.; Palumbo, R. Quercetin: A pleiotropic kinase inhibitor against cancer. Cancer Treat. Res. 2014, 159, 185–205.
15. Ahmad, A.; Biersack, B.; Li, Y.; Bao, B.; Kong, D.; Ali, S.; Banerjee, S.; Sarkar, F.H. Perspectives on the role of isoflavones in prostate cancer. AAPS J. 2013, 15, 991–1000.
16. Genovese, S.; Epifano, F. Auraptene: A natural biologically active compound with multiple targets. Curr. Drug Targets 2011, 12, 381–386.
17. Rather, M.A.; Bhat, B.A.; Qurishi, M.A. Multicomponent phytotherapeutic approach gaining momentum: Is the “one drug to fit all” model breaking down? Phytomedicine 2013, 21, 1–14.
18. Gild, M.L.; Bullock, M.; Robinson, B.G.; Clifton-Bligh, R. Multikinase inhibitors: A new option for the treatment of thyroid cancer. Nat. Rev. Endocrinol. 2011, 7, 617–624.
19. Den Hollander, P.; Savage, M.I.; Brown, P.H. Targeted therapy for breast cancer prevention. Front. Oncol. 2013, 3, doi:10.3389/fonc.2013.00250.
20. Sabnis, G.; Brodie, A. Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance. Mol. Cell Endocrinol. 2011, 340, 142–147.
21. Jones, A. Combining trastuzumab (herceptin) with hormonal therapy in breast cancer: What can be expected and why? Ann. Oncol. 2003, 14, 1697–1704.
22. Shao, Z.M.; Shen, Z.Z.; Liu, C.H.; Sartippour, M.R.; Go, V.L.; Heber, D.; Nguyen, M. Curcumin exerts multiple suppressive effects on human breast carcinoma cells. Int. J. Cancer 2002, 98, 234–240.
23. Somers-Edgar, T.J.; Scandlyn, M.J.; Stuart, E.C.; le Nedelec, M.J.; Valentine, S.P.; Rosengren, R.J. The combination of epigallocatechin gallate and curcumin suppresses ERα-breast cancer cell growth in vitro and in vivo. Int. J. Cancer 2008, 122, 1966–1971.
24. De Amicis, F.; Giordano, F.; Vivacqua, A.; Pellegrino, M.; Panno, M.L.; Tramontano, D.; Fuqua, S.A.; Ando, S. Resveratrol, through Nf-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor alpha gene expression via p38MAPK/CK2 signaling in human breast cancer cells. FASEB J. 2011, 25, 3695–3707.
25. Kang, N.H.; Hwang, K.A.; Lee, H.R.; Choi, D.W.; Choi, K.C. Resveratrol regulates the cell viability promoted by 17beta-estradiol or bisphenol A via down-regulation of the cross-talk between estrogen receptor alpha and insulin growth factor-1 receptor in BG-1 ovarian cancer cells. Food Chem. Toxicol. 2013, 59, 373–379.
26. Rajoria, S.; Suriano, R.; George, A.; Shanmugam, A.; Schantz, S.P.; Geliebter, J.; Tiwari, R.K. Estrogen induced metastatic modulators MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in thyroid cancer. PLoS One 2011, 6, doi:10.1371/journal.pone.0015879.
27. Sun, S.H.; Huang, H.C.; Huang, C.; Lin, J.K. Cycle arrest and apoptosis in MDA-MB-231/Her2 cells induced by curcumin. Eur. J. Pharmacol. 2012, 690, 22–30.
28. Catania, A.; Barrajon-Catalan, E.; Nicolosi, S.; Cicirata, F.; Micol, V. Immunoliposome encapsulation increases cytotoxic activity and selectivity of curcumin and resveratrol against HER2 overexpressing human breast cancer cells. Breast Cancer Res. Treat. 2013, 141, 55–65.
29. McGuire, K.P.; Ngoubilly, N.; Neavyn, M.; Lanza-Jacoby, S. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells. J. Surg. Res. 2006, 132, 208–213.
30. Ahmad, A.; Ali, S.; Ahmed, A.; Ali, A.S.; Raz, A.; Sakr, W.A.; Rahman, K.M. 3,3'-diindolylmethane enhances the effectiveness of herceptin against HER-2/Neu-expressing breast cancer cells. PLoS One 2013, 8, doi:10.1371/journal.pone.0054657.
31. Sarkar, F.H.; Li, Y. Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics. Cancer Treat. Rev. 2009, 35, 597–607.
32. Banerjee, S.; Kong, D.; Wang, Z.; Bao, B.; Hillman, G.G.; Sarkar, F.H. Attenuation of multi-targeted proliferation-linked signaling by 3,3'-diindolylmethane (DIM): From bench to clinic. Mutat. Res. 2011, 728, 47–66.
33. Li, Y.; Kong, D.; Bao, B.; Ahmad, A.; Sarkar, F.H. Induction of cancer cell death by isoflavone: The role of multiple signaling pathways. Nutrients 2011, 3, 877–896.
34. Gupta, S.C.; Prasad, S.; Kim, J.H.; Patchva, S.; Webb, L.J.; Priyadarsini, I.K.; Aggarwal, B.B. Multitargeting by curcumin as revealed by molecular interaction studies. Nat. Prod. Rep. 2011, 28, 1937–1955.
35. Khan, N.; Mukhtar, H. Multitargeted therapy of cancer by green tea polyphenols. Cancer Lett. 2008, 269, 269–280
36. Mukhtar, E.; Adhami, V.M.; Khan, N.; Mukhtar, H. Apoptosis and autophagy induction as mechanism of cancer prevention by naturally occurring dietary agents. Curr. Drug Targets 2012, 13, 1831–1841.
37. Prakobwong, S.; Gupta, S.C.; Kim, J.H.; Sung, B.; Pinlaor, P.; Hiraku, Y.; Wongkham, S.; Sripa, B.; Pinlaor, S.; Aggarwal, B.B. Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways. Carcinogenesis 2011, 32, 1372–1380.
38. Kim, S.H.; Sehrawat, A.; Singh, S.V. Dietary chemopreventative benzyl isothiocyanate inhibits breast cancer stem cells in vitro and in vivo. Cancer Prev. Res. (Phila) 2013, 6, 782–790.
39. Bao, B.; Li, Y.; Ahmad, A.; Azmi, A.S.; Bao, G.; Ali, S.; Banerjee, S.; Kong, D.; Sarkar, F.H. Targeting CSC-related mirnas for cancer therapy by natural agents. Curr. Drug Targets 2012, 13, 1858–1868.
40. Dandawate, P.; Padhye, S.; Ahmad, A.; Sarkar, F.H. Novel strategies targeting cancer stem cells through phytochemicals and their analogs. Drug Deliv. Transl. Res. 2013, 3, 165–182.
41. Li, Y.; Kong, D.; Wang, Z.; Sarkar, F.H. Regulation of micrornas by natural agents: An emerging field in chemoprevention and chemotherapy research. Pharm. Res. 2010, 27, 1027–1041.
42. Saini, S.; Majid, S.; Dahiya, R. Diet, micrornas and prostate cancer. Pharm. Res. 2010, 27, 1014–1026.
43. Chiyomaru, T.; Yamamura, S.; Fukuhara, S.; Yoshino, H.; Kinoshita, T.; Majid, S.; Saini, S.; Chang, I.; Tanaka, Y.; Enokida, H.; et al. Genistein inhibits prostate cancer cell growth by targeting miR-34a and oncogenic hotair. PLoS One 2013, 8, doi:10.1371/journal.pone.0070372.
44. Li, W.; Ma, J.; Ma, Q.; Li, B.; Han, L.; Liu, J.; Xu, Q.; Duan, W.; Yu, S.; Wang, F.; et al. Resveratrol inhibits the epithelial-mesenchymal transition of pancreatic cancer cells via suppression of the PI-3k/Akt/NF-κB pathway. Curr. Med. Chem. 2013, 20, 4185–4194.
45. Baribeau, S.; Chaudhry, P.; Parent, S.; Asselin, E. Resveratrol inhibits cisplatin-induced epithelial-to-mesenchymal transition in ovarian cancer cell lines. PLoS One 2014, 9, doi:10.1371/ journal.pone.0086987.
46. Ahmad, A.; Li, Y.; Bao, B.; Kong, D.; Sarkar, F.H. Epigenetic regulation of mirna-cancer stem cells nexus by nutraceuticals. Mol. Nutr. Food Res. 2014, 58, 79–86.
47. Hirata, H.; Hinoda, Y.; Shahryari, V.; Deng, G.; Tanaka, Y.; Tabatabai, Z.L.; Dahiya, R. Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells. Br. J. Cancer 2014, 110, 1645–1654.
48. Siddiqui, I.A.; Adhami, V.M.; Bharali, D.J.; Hafeez, B.B.; Asim, M.; Khwaja, S.I.; Ahmad, N.; Cui, H.; Mousa, S.A.; Mukhtar, H. Introducing nanochemoprevention as a novel approach for cancer control: Proof of principle with green tea polyphenol epigallocatechin-3-gallate. Cancer Res. 2009, 69, 1712–1716.
49. Siddiqui, I.A.; Mukhtar, H. Nanochemoprevention by bioactive food components: A perspective. Pharm. Res. 2010, 27, 1054–1060.
50. Siddiqui, I.A.; Adhami, V.M.; Ahmad, N.; Mukhtar, H. Nanochemoprevention: Sustained release of bioactive food components for cancer prevention. Nutr. Cancer 2010, 62, 883–890.
51. Johnson, J.J.; Nihal, M.; Siddiqui, I.A.; Scarlett, C.O.; Bailey, H.H.; Mukhtar, H.; Ahmad, N. Enhancing the bioavailability of resveratrol by combining it with piperine. Mol. Nutr. Food Res. 2011, 55, 1169–1176.
52. Sanna, V.; Siddiqui, I.A.; Sechi, M.; Mukhtar, H. Resveratrol-loaded nanoparticles based on poly(epsilon-caprolactone) and poly(D,L-lactic-co-glycolic acid)-poly(ethylene glycol) blend for prostate cancer treatment. Mol. Pharm. 2013, 10, 3871–3881.
53. Khan, N.; Bharali, D.J.; Adhami, V.M.; Siddiqui, I.A.; Cui, H.; Shabana, S.M.; Mousa, S.A.; Mukhtar, H. Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol egcg effectively inhibits prostate cancer cell growth in a xenograft model. Carcinogenesis 2014, 35, 415–423.
54. Mimeault, M.; Batra, S.K. Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy. Chin. Med. 2011, 6, doi:10.1186/1749-8546-6-31.
55. Pando, D.; Caddeo, C.; Manconi, M.; Fadda, A.M.; Pazos, C. Nanodesign of olein vesicles for the topical delivery of the antioxidant resveratrol. J. Pharm. Pharmacol. 2013, 65, 1158–1167.
56. Saxena, V.; Hussain, M.D. Polymeric mixed micelles for delivery of curcumin to multidrug resistant ovarian cancer. J. Biomed. Nanotechnol. 2013, 9, 1146–1154.
57. Ogas, T.; Kondratyuk, T.P.; Pezzuto, J.M. Resveratrol analogs: Promising chemopreventive agents. Ann. N. Y. Acad. Sci. 2013, 1290, 21–29.
58. Saiko, P.; Graser, G.; Giessrigl, B.; Steinmann, M.T.; Schuster, H.; Lackner, A.; Grusch, M.; Krupitza, G.; Jaeger, W.; Somepalli, V.; et al. Digalloylresveratrol, a novel resveratrol analog inhibits the growth of human pancreatic cancer cells. Investig. New Drugs 2013, 31, 1115–1124.
59. Pezzuto, J.M.; Kondratyuk, T.P.; Ogas, T. Resveratrol derivatives: A patent review (2009–2012). Expert Opin. Ther. Pat. 2013, 23, 1529–1546.
60. Oskarsson, A.; Spatafora, C.; Tringali, C.; Andersson, A.O. Inhibition of CYP17A1 activity by resveratrol, piceatannol, and synthetic resveratrol analogs. Prostate 2014, 74, 839–851.
61. Kucinska, M.; Piotrowska, H.; Luczak, M.W.; Mikula-Pietrasik, J.; Ksiazek, K.; Wozniak, M.; Wierzchowski, M.; Dudka, J.; Jager, W.; Murias, M. Effects of hydroxylated resveratrol analogs on oxidative stress and cancer cells death in human acute T cell leukemia cell line: Prooxidative potential of hydroxylated resveratrol analogs. Chem. Biol. Interact. 2014, 209, 96–110.
62. Ciochina, R.; Savella, C.; Cote, B.; Chang, D.; Rao, D. Synthesis and characterization of new curcumin derivatives as potential chemotherapeutic and antioxidant agents. Drug Dev. Res. 2014, 75, 88–96.
63. Campos, C.A.; Gianino, J.B.; Bailey, B.J.; Baluyut, M.E.; Wiek, C.; Hanenberg, H.; Shannon, H.E.; Pollok, K.E.; Ashfeld, B.L. Design, synthesis, and evaluation of curcumin-derived arylheptanoids for glioblastoma and neuroblastoma cytotoxicity. Bioorg. Med. Chem. Lett. 2013, 23, 6874–6878.
64. Liu, Z.; Sun, Y.; Ren, L.; Huang, Y.; Cai, Y.; Weng, Q.; Shen, X.; Li, X.; Liang, G.; Wang, Y. Evaluation of a curcumin analog as an anti-cancer agent inducing er stress-mediated apoptosis in non-small cell lung cancer cells. BMC Cancer 2013, 13, doi:10.1186/1471-2407-13-494.
65. Nagaraju, G.P.; Zhu, S.; Wen, J.; Farris, A.B.; Adsay, V.N.; Diaz, R.; Snyder, J.P.; Mamoru, S.; El-Rayes, B.F. Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer. Cancer Lett. 2013, 341, 195–203.
66. Samaan, N.; Zhong, Q.; Fernandez, J.; Chen, G.; Hussain, A.M.; Zheng, S.; Wang, G.; Chen, Q.H. Design, synthesis, and evaluation of novel heteroaromatic analogs of curcumin as anti-cancer agents. Eur. J. Med. Chem. 2014, 75, 123–131.
67. Yadav, I.S.; Nandekar, P.P.; Shrivastava, S.; Sangamwar, A.; Chaudhury, A.; Agarwal, S.M. Ensemble docking and molecular dynamics identify knoevenagel curcumin derivatives with potent anti-egfr activity. Gene 2014, 539, 82–90.
68. Yang, H.; Sun, D.K.; Chen, D.; Cui, Q.C.; Gu, Y.Y.; Jiang, T.; Chen, W.; Wan, S.B.; Dou, Q.P. Antitumor activity of novel fluoro-substituted (-)-epigallocatechin-3-gallate analogs. Cancer Lett. 2010, 292, 48–53.
69. Kanwar, J.; Mohammad, I.; Yang, H.; Huo, C.; Chan, T.H.; Dou, Q.P. Computational modeling of the potential interactions of the proteasome beta5 subunit and catechol-o-methyltransferase-resistant egcg analogs. Int. J. Mol. Med. 2010, 26, 209–215.
70. Shin, J.A.; Shim, J.H.; Choi, E.S.; Leem, D.H.; Kwon, K.H.; Lee, S.O.; Safe, S.; Cho, N.P.; Cho, S.D. Chemopreventive effects of synthetic C-substituted diindolylmethanes originating from cruciferous vegetables in human oral cancer cells. Eur. J. Cancer Prev
71. Abdelbaqi, K.; Lack, N.; Guns, E.T.; Kotha, L.; Safe, S.; Sanderson, J.T. Antiandrogenic and growth inhibitory effects of ring-substituted analogs of 3,3'-diindolylmethane (ring-dims) in hormone-responsive lncap human prostate cancer cells. Prostate 2011, 71, 1401–1412.
72. Andey, T.; Patel, A.; Jackson, T.; Safe, S.; Singh, M. 1,1-bis (3'-indolyl)-1-(p-substitutedphenyl)methane compounds inhibit lung cancer cell and tumor growth in a metastasis model. Eur. J. Pharm. Sci. 2013, 50, 227–241.
73. Goldberg, A.A.; Titorenko, V.I.; Beach, A.; Abdelbaqi, K.; Safe, S.; Sanderson, J.T. Ring-substituted analogs of 3,3'-diindolylmethane (DIM) induce apoptosis and necrosis in androgen-dependent and -independent prostate cancer cells. Investig. New Drugs 2014, 32, 25–36.
74. Ahmad, A.; Biersack, B.; Li, Y.; Kong, D.; Bao, B.; Schobert, R.; Padhye, S.B.; Sarkar, F.H. Targeted regulation of PI3K/Akt/mTOR/NF-κB signaling by indole compounds and their derivatives: Mechanistic details and biological implications for cancer therapy. Anticancer Agents Med. Chem. 2013, 13, 1002–1013.
75. Padhye, S.; Yang, H.; Jamadar, A.; Cui, Q.C.; Chavan, D.; Dominiak, K.; McKinney, J.; Banerjee, S.; Dou, Q.P.; Sarkar, F.H. New difluoro knoevenagel condensates of curcumin, their schiff bases and copper complexes as proteasome inhibitors and apoptosis inducers in cancer cells. Pharm. Res. 2009, 26, 1874–1880.
76. Padhye, S.; Banerjee, S.; Chavan, D.; Pandye, S.; Swamy, K.V.; Ali, S.; Li, J.; Dou, Q.P.; Sarkar, F.H. Fluorocurcumins as cyclooxygenase-2 inhibitor: Molecular docking, pharmacokinetics and tissue distribution in mice. Pharm. Res. 2009, 26, 2438–2445.
77. Kanwar, S.S.; Yu, Y.; Nautiyal, J.; Patel, B.B.; Padhye, S.; Sarkar, F.H.; Majumdar, A.P. Difluorinated-curcumin (CDF): A novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Pharm. Res. 2011, 28, 827–838.
78. Bao, B.; Ahmad, A.; Li, Y.; Azmi, A.S.; Ali, S.; Banerjee, S.; Kong, D.; Sarkar, F.H. Targeting cscs within the tumor microenvironment for cancer therapy: A potential role of mesenchymal stem cells. Expert Opin. Ther. Targets 2012, 16, 1041–1054.
79. Ali, S.; Ahmad, A.; Aboukameel, A.; Bao, B.; Padhye, S.; Philip, P.A.; Sarkar, F.H. Increased ras gtpase activity is regulated by mirnas that can be attenuated by CDF treatment in pancreatic cancer cells. Cancer Lett. 2012, 319, 173–181.
80. Dandawate, P.R.; Vyas, A.; Ahmad, A.; Banerjee, S.; Deshpande, J.; Swamy, K.V.; Jamadar, A.; Dumhe-Klaire, A.C.; Padhye, S.; Sarkar, F.H. Inclusion complex of novel curcumin analogue CDF and beta-cyclodextrin (1:2) and its enhanced in vivo anticancer activity against pancreatic cancer. Pharm. Res. 2012, 29, 1775–1786.
81. Roy, S.; Yu, Y.; Padhye, S.B.; Sarkar, F.H.; Majumdar, A.P. Difluorinated-curcumin (CDF) restores pten expression in colon cancer cells by down-regulating MIR-21. PLoS One 2013, 8, doi:10.1371/journal.pone.0068543.
82. Karin, M. Nf-κB and cancer: Mechanisms and targets. Mol. Carcinog. 2006, 45, 355–361.
83. Karin, M. Nuclear factor-κB in cancer development and progression. Nature 2006, 441, 431–436.
84. Ben-Neriah, Y.; Karin, M. Inflammation meets cancer, with NF-κB as the matchmaker. Nat. Immunol. 2011, 12, 715–723.
85. DiDonato, J.A.; Mercurio, F.; Karin, M. NF-κB and the link between inflammation and cancer. Immunol. Rev. 2012, 246, 379–400.
86. Kunnumakkara, A.B.; Diagaradjane, P.; Guha, S.; Deorukhkar, A.; Shentu, S.; Aggarwal, B.B.; Krishnan, S. Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-κB-regulated gene products. Clin. Cancer Res. 2008, 14, 2128–2136.
87. Kamat, A.M.; Tharakan, S.T.; Sung, B.; Aggarwal, B.B. Curcumin potentiates the antitumor effects of bacillus calmette-guerin against bladder cancer through the downregulation of Nf-κB and upregulation of trail receptors. Cancer Res. 2009, 69, 8958–8966.
88. Zhang, C.; Li, B.; Zhang, X.; Hazarika, P.; Aggarwal, B.B.; Duvic, M. Curcumin selectively induces apoptosis in cutaneous T-cell lymphoma cell lines and patients’ PBMCS: Potential role for STAT-3 and NF-κB signaling. J. Investig. Dermatol. 2010, 130, 2110–2119.
89. Kim, J.H.; Gupta, S.C.; Park, B.; Yadav, V.R.; Aggarwal, B.B. Turmeric (Curcuma longa) inhibits inflammatory nuclear factor (NF)-κB and NF-κB-regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis. Mol. Nutr. Food Res. 2012, 56, 454–465.
90. Sung, B.; Prasad, S.; Yadav, V.R.; Aggarwal, B.B. Cancer cell signaling pathways targeted by spice-derived nutraceuticals. Nutr. Cancer 2012, 64, 173–197.
91. Sarkar, F.H.; Li, Y. NF-κB: A potential target for cancer chemoprevention and therapy. Front. Biosci. 2008, 13, 2950–2959.
92. Sarkar, F.H.; Li, Y.; Wang, Z.; Kong, D. NF-κB signaling pathway and its therapeutic implications in human diseases. Int. Rev. Immunol. 2008, 27, 293–319.
93. Gerhauser, C. Cancer chemoprevention and nutriepigenetics: State of the art and future challenges. Top. Curr. Chem. 2013, 329, 73–132.
94. Pal, S.; Bhattacharjee, A.; Ali, A.; Mandal, N.C.; Mandal, S.C.; Pal, M. Chronic inflammation and cancer: Potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism. J. Inflamm. (Lond.) 2014, 11, doi:10.1186/1476-9255-11-23.
95. Gupta, S.C.; Kim, J.H.; Kannappan, R.; Reuter, S.; Dougherty, P.M.; Aggarwal, B.B. Role of nuclear factor κB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents. Exp. Biol. Med. (Maywood.) 2011, 236, 658–671.